Von Gruenhagen Ulrich - Outpatient Clin, Cottbus, Germany

基本信息

浏览量：9

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 20 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group

Thoralf Lange,Christian Niederwieser,Arthur Gil,Rainer Krahl,Ulrich von Gruenhagen,Haifa Kathrin Al-Ali,Kathleen Jentsch-Ullrich,Claudia Spohn,Volker Lakner,Michael Assmann,Christian Junghanss,Michael Cross,Ruediger Hehlmann,Michael Deininger,Markus Pfirrmann,Dietger Niederwieser

LEUKEMIA & LYMPHOMA（2020）

引用0浏览0WOS引用

Imatinib (IM) in Combination with Hydroxyurea in Patients with CML1st CP Does Not Increase Molecular Response at 18 Months Compared to IM Alone. Final Results of the OSHO CML2004 Study. NCT 02480608

T. Lange,R. Krahl,U. von Gruenhagen,H. K. Al-Ali,A. Schwarzer,K. Jentsch-Ullrich,C. Spohn,V. Lakner,M. Assmann,C. Junghanss,M. Pfirrmann,A. Gil,R. Hehlmann,M. Deininger,D. Niederwieser

Onkologie（2017）

引用23浏览0引用

Imatinib (im) 400mg in Patients with Cml1st Cp Results in A Higher Molecular Response Rate at 6 Months Compared to Im/Hydroxyurea. Final Results of the Cml2004 Study. Nct 02480608

T. Lange,R. Krahl,U. von Gruenhagen,H. K. Al-Ali,A. Schwarzer,R. Uhle,C. Spohn,V. Lakner,M. Assmann,C. Junghanss,M. Pfirrmann,A. Gil,R. Hehlmann,M. Deininger,D. Niederwieser

Haematologica（2017）

引用22浏览0引用

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab for Patients with Relapsed Indolent and Mantle-Cell Lymphomas: a Multicentre, Randomised, Open-Label, Non-Inferiority Phase 3 Trial

Mathias Rummel,Ulrich Kaiser,Christina Balser,Martina Stauch,Wolfram Brugger,Manfred Welslau,Norbert Niederle,Christoph Losem,Hans-Peter Boeck,Eckhart Weidmann,Ulrich von Gruenhagen,Lothar Mueller,Michael Sandherr,Lars Hahn, Julia Vereshchagina,Frank Kauff,Wolfgang Blau,Axel Hinke,Juergen Barth

Lancet oncology/Lancet Oncologyno. 1 (2016): 57-66

引用129浏览0WOS引用

129

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (study Group Indolent Lymphomas, Germany)

Mathias J. Rummel,Ulrich Kaiser,Christina Balser,Martina Beate Stauch,Wolfram Brugger,Manfred Welslau,Norbert Niederle,Christoph Losem,Harald Ballo,Eckhart Weidmann,Ulrich von Gruenhagen,Lothar Mueller,Michael Sandherr, Julia Vereschagina,Axel Hinke,Juergen Barth

Blood（2010）

引用13浏览0引用

SUSTAINED SURVIVAL ADVANTAGE AFTER A MEDIAN FOLLOW-UP OF 5 YEARS FOR IMMUNO-CHEMOTHERAPY (R-MCP) VERSUS CHEMOTHERAPY ALONE (MCP) IN ADVANCED FOLLICULAR LYMPHOMA - UPDATE OF THE OSHO#39 TRIAL

M. Herold,G. Maschmeyer,V. Lakner,G. Doelken, G. Ehninger,M. Haenel,R. Rohrberg,A. Hochhaus,A. Neubauer, L. Fischer,U. von Gruenhagen,S. Hahnfeld, F. Hoffmann,M. Wussling,W. Stein,E. Kettner,D. Haehling

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL（2010）

引用0浏览0引用

Long-term Progression-Free Survival (PFS) in Patients with Metastatic Breast Cancer (BC) Treated with Tandem Autologous Followed by Allogeneic Stem Cell Transplantation (SCT)

C. Becker,H. Al-Ali, D. Langanke,F. Hoffmann,U. von Gruenhagen,D. Niederwieser

Journal of Clinical Oncology（2010）

引用0浏览0引用

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial on Behalf of an International Group of Investigators and the German CLL Study Gro..

Blood（2009）

引用50浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn